검색
AbbVie Inc
ABBV관심 목록에 추가
201.550USD
-1.350-0.67%
종가 05/08, 16:00（ET）시세는 15분 지연됩니다
356.49B시가총액
98.93P/E TTM
자세한 내용은 AbbVie Inc 회사
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
AbbVie Inc 정보
종목 코드 ABBV
회사 이름AbbVie Inc
상장일Jan 02, 2013
CEOMichael (Robert A)
직원 수55000
유형Ordinary Share
회계 연도 종료Jan 02
주소1 N Waukegan Rd
도시NORTH CHICAGO
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호60064
전화18479327900
웹사이트https://www.abbvie.com/
종목 코드 ABBV
상장일Jan 02, 2013
CEOMichael (Robert A)
AbbVie Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
--
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
44.85K
+4.23%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
--
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
--
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
--
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-346.66%
Mr. Thomas J. (Tom) Falk
Mr. Thomas J. (Tom) Falk
Independent Director
Independent Director
4.20K
+42.76%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
--
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
44.85K
+4.23%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
--
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--
수익 분석
통화: USD마지막 업데이트: Mon, Apr 6
통화: USD마지막 업데이트: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Immunology-SKYRIZI
17.56B
28.71%
Immunology-RINVOQ
8.30B
13.58%
Immunology-HUMIRA
4.54B
7.42%
Neuroscience-Botox Therapeutic
3.77B
6.16%
Neuroscience-Vraylar
3.62B
5.92%
기타
23.36B
38.20%
지역별USD
이름
수익
비율
United States
44.49B
72.75%
International
13.04B
21.32%
All other countries
2.63B
4.30%
Germany
1.74B
2.84%
Japan
1.27B
2.08%
기타
-2.01B
-3.29%
사업별
지역별
사업별USD
이름
수익
비율
Immunology-SKYRIZI
17.56B
28.71%
Immunology-RINVOQ
8.30B
13.58%
Immunology-HUMIRA
4.54B
7.42%
Neuroscience-Botox Therapeutic
3.77B
6.16%
Neuroscience-Vraylar
3.62B
5.92%
기타
23.36B
38.20%
주식 보유 통계
마지막 업데이트: 4 hours ago
마지막 업데이트: 4 hours ago
주주
주주 유형
주주
주주
비율
Vanguard Capital Management, LLC
6.50%
BlackRock Institutional Trust Company, N.A.
5.38%
State Street Investment Management (US)
4.58%
Vanguard Portfolio Management, LLC
2.80%
Geode Capital Management, L.L.C.
2.52%
기타
78.23%
주주
주주
비율
Vanguard Capital Management, LLC
6.50%
BlackRock Institutional Trust Company, N.A.
5.38%
State Street Investment Management (US)
4.58%
Vanguard Portfolio Management, LLC
2.80%
Geode Capital Management, L.L.C.
2.52%
기타
78.23%
주주 유형
주주
비율
Investment Advisor
54.81%
Investment Advisor/Hedge Fund
21.61%
Research Firm
3.14%
Bank and Trust
2.37%
Pension Fund
2.27%
Sovereign Wealth Fund
1.54%
Insurance Company
0.67%
Hedge Fund
0.45%
Family Office
0.22%
기타
12.91%
기관 주식 보유
마지막 업데이트: Wed, Apr 1
마지막 업데이트: Wed, Apr 1
보고 기간
기관 수
보유 주식
비율
변동
2026Q1
5703
1.36B
77.09%
+26.64M
2025Q4
5311
1.33B
74.86%
+1.37M
2025Q3
5386
1.32B
74.95%
+8.86M
2025Q2
5326
1.32B
74.78%
+2.41M
2025Q1
5334
1.32B
74.15%
+3.84M
2024Q4
5267
1.31B
73.92%
+9.35M
2024Q3
4970
1.30B
74.13%
-1.24M
2024Q2
4907
1.30B
73.33%
+14.47M
2024Q1
4916
1.28B
72.48%
+1.37M
2023Q4
4861
1.27B
72.12%
+10.24M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
BlackRock Institutional Trust Company, N.A.
95.07M
5.38%
+2.29M
+2.47%
Dec 31, 2025
State Street Investment Management (US)
80.94M
4.58%
+1.12M
+1.40%
Dec 31, 2025
Geode Capital Management, L.L.C.
44.63M
2.52%
+4.19M
+10.36%
Dec 31, 2025
JP Morgan Asset Management
34.79M
1.97%
-1.63M
-4.49%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
25.67M
1.45%
+2.57M
+11.11%
Dec 31, 2025
Capital Research Global Investors
25.41M
1.44%
+177.37K
+0.70%
Dec 31, 2025
Charles Schwab Investment Management, Inc.
25.17M
1.42%
-788.26K
-3.04%
Dec 31, 2025
Fidelity Management & Research Company LLC
21.48M
1.21%
+1.53M
+7.67%
Dec 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
VanEck Pharmaceutical ETF
9.64%
First Trust NASDAQ Pharmaceuticals ETF
8.05%
Health Care Select Sector SPDR Fund
7.89%
Proshares Ultra Health Care
7.62%
iShares U.S. Healthcare ETF
7.57%
JPMorgan Healthcare Leaders ETF
6.87%
Simplify Health Care ETF
6.73%
Fidelity MSCI Health Care Index ETF
6.5%
Harbor Health Care ETF
6.18%
iShares Core High Dividend ETF
5.9%
더 보기
VanEck Pharmaceutical ETF
비율9.64%
First Trust NASDAQ Pharmaceuticals ETF
비율8.05%
Health Care Select Sector SPDR Fund
비율7.89%
Proshares Ultra Health Care
비율7.62%
iShares U.S. Healthcare ETF
비율7.57%
JPMorgan Healthcare Leaders ETF
비율6.87%
Simplify Health Care ETF
비율6.73%
Fidelity MSCI Health Care Index ETF
비율6.5%
Harbor Health Care ETF
비율6.18%
iShares Core High Dividend ETF
비율5.9%
주식 배당금
지난 5년 동안 총
40.87B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Feb 19, 2026
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on May 15, 2026 going ex on Apr 15, 2026 with reinvestment option
Apr 15, 2026
May 15, 2026
Apr 15, 2026
Oct 31, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option
Jan 16, 2026
Feb 17, 2026
Jan 16, 2026
Sep 05, 2025
ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 14, 2025
Oct 15, 2025
Jun 20, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 13, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
더 보기
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
